{"entity":{"id":"ba3071","kind":"drug","name":"BA3071","aka":[],"tldr":"BA3071 is an experimental monoclonal antibody from BioAtla in phase 2 trials for non-small-cell lung cancer and melanoma, aimed at CTLA-4.","summary":"BA3071 is a monoclonal antibody developed by BioAtla. Its target is CTLA-4 (the sponsor names CTLA-4). The sponsor states: A Conditionally Active Biologic (CAB-C) anti-CTLA-4 antibody engineered to bind and block CTLA-4 preferentially within the tumour microenvironment (rather than systemically), activating T cells locally to reduce systemic toxicity. ClinicalTrials.gov describes the intervention as: Conditionally active biologic (CAB) antibody that binds to CTLA-4. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, in non-small-cell lung cancer and melanoma. The largest, NCT05180799, plans to enrol 320 participants with primary completion was scheduled for 2025-03-19 on the registry. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.","status":"phase-2","asOf":"2026-09-11","links":[{"label":"ClinicalTrials.gov: trials of BA3071","url":"https://clinicaltrials.gov/search?intr=BA3071"},{"label":"Sponsor pipeline page","url":"https://www.bioatla.com/cab-portfolio/"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["nsclc","melanoma"],"sections":[],"technologies":[],"targets":["ctla4"],"drugs":[],"companies":["bioatla"],"institutions":[],"pathways":[],"terms":[],"trials":["nct05180799"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor pipeline pages)","editedOn":"2026-09-11"},"modality":"monoclonal antibody","mechanism":"A Conditionally Active Biologic (CAB-C) anti-CTLA-4 antibody engineered to bind and block CTLA-4 preferentially within the tumour microenvironment (rather than systemically), activating T cells locally to reduce systemic toxicity.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/ba3071/","neighbours":{"cancer":[{"id":"melanoma","kind":"cancer","name":"Melanoma","route":"/cancers/melanoma/"},{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"}],"target":[{"id":"ctla4","kind":"target","name":"CTLA-4","route":"/targets/ctla4/"}],"company":[{"id":"bioatla","kind":"company","name":"BioAtla","route":"/companies/bioatla/"}],"trial":[{"id":"nct05180799","kind":"trial","name":"A Phase 1/2 Study of BA3071 in Patients With Solid Tumors","route":"/trials/nct05180799/"}]}}